281 related articles for article (PubMed ID: 31390276)
1. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R
J Clin Oncol; 2019 Oct; 37(28):2571-2580. PubMed ID: 31390276
[TBL] [Abstract][Full Text] [Related]
2. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
3. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
4. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.
Lamberti G; Faggiano A; Brighi N; Tafuto S; Ibrahim T; Brizzi MP; Pusceddu S; Albertelli M; Massironi S; Panzuto F; Badalamenti G; Riccardi F; Butturini G; Gelsomino F; De Divitiis C; Modica R; Bongiovanni A; La Salvia A; Torchio M; Colao A; Ferone D; Campana D
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31545377
[TBL] [Abstract][Full Text] [Related]
5.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
7. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
8. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
12. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
[No Abstract] [Full Text] [Related]
14. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
16. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
18. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK
BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646
[TBL] [Abstract][Full Text] [Related]
19. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
[No Abstract] [Full Text] [Related]
20. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
